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Abstract
Objective: The endogenous, cholestatic metabolite estradiol 17ß-D-glucuronide (E217G) induces endocytic internalization of
the canalicular transporters relevant to bile formation, Bsep and Mrp2. We evaluated here whether MAPKs are involved in
this effect.
Design: ERK1/2, JNK1/2, and p38 MAPK activation was assessed by the increase in their phosphorylation status.
Hepatocanalicular function was evaluated in isolated rat hepatocyte couplets (IRHCs) by quantifying the apical secretion of
fluorescent Bsep and Mrp2 substrates, and in isolated, perfused rat livers (IPRLs), using taurocholate and 2,4-dinitrophenyl-S-
glutathione, respectively. Protein kinase participation in E217G-induced secretory failure was assessed by co-administering
selective inhibitors. Internalization of Bsep/Mrp2 was assessed by confocal microscopy and image analysis.
Results: E217G activated all kinds of MAPKs. The PI3K inhibitor wortmannin prevented ERK1/2 activation, whereas the cPKC
inhibitor Go¨6976 prevented p38 activation, suggesting that ERK1/2 and p38 are downstream of PI3K and cPKC, respectively.
The p38 inhibitor SB203580 and the ERK1/2 inhibitor PD98059, but not the JNK1/2 inhibitor SP600125, partially prevented
E217G-induced changes in transporter activity and localization in IRHCs. p38 and ERK1/2 co-inhibition resulted in additive
protection, suggesting complementary involvement of these MAPKs. In IPRLs, E217G induced endocytosis of canalicular
transporters and a rapid and sustained decrease in bile flow and biliary excretion of Bsep/Mrp2 substrates. p38 inhibition
prevented this initial decay, and the internalization of Bsep/Mrp2. Contrarily, ERK1/2 inhibition accelerated the recovery of
biliary secretion and the canalicular reinsertion of Bsep/Mrp2.
Conclusions: cPKC/p38 MAPK and PI3K/ERK1/2 signalling pathways participate complementarily in E217G-induced
cholestasis, through internalization and sustained intracellular retention of canalicular transporters, respectively.
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Introduction
Bile formation is a highly regulated process that depends upon
the coordinated transport activity of basolateral and canalicular
carriers on the hepatocyte. Complex signalling pathways regulate
the density and activity of these carriers, and its imbalance impairs
secretory function, leading to retention of biliary components both
in liver and blood [1].
Estradiol 17ß-D-glucuronide (E217G) is an endogenous metab-
olite of 17ß-estradiol that induces an acute, reversible cholestasis in
rats [2]. Since its level build up during pregnancy, it has been
suggested to be relevant to the pathogenesis of intrahepatic
cholestasis in pregnant, susceptible women [2].
The mechanisms involved in E217G induces cholestasis seems
to be multifactorial. Trans-inhibition by E217G of Bsep-mediated
canalicular transport of bile salts [3] and increase in paracellular
permeability leading to dissipation of plasma-to-bile osmotic
gradients [4] have been shown to be causal factors. In addition,
our group showed that endocytic internalization of both Bsep [5]
and Mrp2 [6,7], two canalicular transporters crucial for bile
formation, is also a key cholestatic mechanism. In addition, our
group also demonstrated that E217G activates both classical (Ca
2+-
dependent) protein kinase C (cPKC) isoforms [8] and the
phosphoinositide 3-kinase (PI3K)-Akt signalling pathway [9], and
that these signalling events are cooperatively involved in the
changes in Bsep/Mrp2 localization status. Whereas cPKC triggers
endocytic internalization of these transporters, PI3K-Akt retains
them into intracellular, vesicular compartments [8,9].
Since the biological effects of cPKC and PI3K are often
mediated through downstream protein kinases, we speculated that
other signalling mediators are involved, provided they can
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e49255
crosstalk with cPKC or PI3K. Likely candidates are the mitogen
activated protein kinases (MAPKs). Both cPKC [10,11] and
PI3K/Akt [12,13] often act as upstream signalling activators of
MAPKs in hepatocytes.
The main vertebrate MAPKs are the extracellular signal-
regulated kinases 1 and 2 (ERK1/2), c-Jun amino-terminal kinases
1 and 2 (JNK1/2), and p38 kinase (isoforms a and b in
hepatocytes). ERK1/2 is preferentially activated by growth
factors, while JNK1/2 and p38 are more responsive to stress
stimuli [14]. After recognition of these effectors by surface
receptors, MAPKs are activated by three-tiered, sequential
phosphorylations mediated by small GTP-binding proteins (e.g.,
Ras, Rap) and two protein kinases (MAPKKK and MAPKK),
which act as dual-specificity enzymes that activate a selective
MAPK type. Non-canonical activation of MAPKs involves MAPK
autophosphorylation, or direct MAPK phosphorylation by alter-
native protein kinases, such as Src or ZAP70 [15].
Supporting MAPK involvement in E217G-induced cholestasis,
17ß-estradiol, a E217G precursor which evokes in hepatocyte-
derived cell lines most signalling pathways activated by E217G
(including the cholestatic ones, cPKC [16] and PI3K [17]),
activates MAPKs in several cell types, such as cardiomiocytes [18],
neurons [19], and cholangiocytes [20]. Furthermore, many rapid
responses of estrogens are mediated by MAPKs, particularly of the
ERK1/2 and p38 MAPK types [21]. Even more suggestively, the
cholestatic bile salt taurolithocholate (TLC), which shares with
E217G the capability to evoke the pro-cholestatic route mediated
by PI3K [22], activates p38 in isolated rat hepatocytes [23].
These findings have prompted us to study the role for MAPKs
in E217G-induced cholestasis. In particular, we ascertained which
MAPK types contribute to E217G-induced cholestasis both in
isolated rat hepatocyte couplets (IRHCs) and in the isolated,
perfused rat liver (IPRL). Our results demonstrate that both p38
and ERK1/2 contribute to the impairment of localization and
function of Bsep and Mrp2 induced by E217G, by acting in a
complementary manner, and downstream of cPKC and PI3K,
respectively.
Materials and Methods
Materials
Cholyl-glycylamido-fluorescein (CGamF) was a generous gift
from Prof. Alan Hofmann (University of California, San Diego).
E217G, collagenase type A (from Clostridium histolyticum), bovine
serum albumin (BSA), trypan blue, L-15 culture medium, dimethyl
sulfoxide (DMSO), Triton X-100, ethylene glycol tetraacetic acid,
sodium dodecyl sulfate, tetramethylethylenediamine, dithiothrei-
tol, ammonium persulfate, urethane, protease inhibitor cocktail, b
nicotinamide adenine dinucleotide hydrate and, 1-chloro-2,4-
dinitrobenzene (CDNB) were from Sigma Chemical Co. (St.
Louis, MO, USA). 5-Chloromethylfluorescein diacetate (CMFDA)
was from Molecular Probes (Eugene, OR, USA). Go¨6976,
SB203580, PD980589, SP 600125, and sodium taurocholate were
from Calbiochem (San Diego, CA, USA). Wortmannin (WM) was
from Fluka AG (Buchs, Switzerland). Cell lysis buffer was from
Cell Signaling Technology (Beverly, MA). The chemiluminescence
reagent, and Hyperfilm ECL were from Thermo Fisher Scientific,
Inc. (Waltham, MA, USA). All the other reagents were of
analytical-grade.
Ethics Statement
All animals received humane care according to the criteria
outlined in the ‘‘Guide for the Care and Use of Laboratory
Animals’’ Eight Edition (National Academy of Sciences, 2011).
Experimental procedures were carried out according to the local
Guideline for the Use of Laboratory Animals (Resolution Nu
6109/012) established by the institutional Bioethical Committee
for the Management of Laboratory Animals and approved by the
Faculty of Biochemical and Pharmaceutical Sciences of the
National University of Rosario. A system of local committee-
based regulatory control offers an equivalent level of regulatory
control to that exercised by the systems in Canada. The guidelines
for the use of laboratory animals has been approved by our Faculty
in 2002, based on CCAC (Canadian Council on Animal Care)
guidelines documents. The document has been updated since then
according to current and emerging issues for the research
community and to advances in laboratory animal care.
Animals
Adult female Wistar rats weighing 250–300 g and bred in our
animal house as described [24], were used in all studies.
Treatment were carried out under urethane anesthesia (1 g/kg
intraperitoneally), and maintained thus throughout. When neces-
sary, body temperature was measured with a rectal probe and
maintained at 37uC.
Isolation and Culture of IRHCs
To obtain a preparation enriched in IRHCs, livers were
perfused according to the two-step collagenase perfusion proce-
dure, and further enriched by centrifugal elutriation [25]. Cell
viability, assessed by trypan blue exclusion, was greater than 90%.
To allow for restoration of their polarity, IRHCs were plated onto
24-well plastic plates at a density of 0.56105 U/mL in L-15
culture medium, and cultured for 5 h.
IRHC treatments
IRHCs were exposed to the vehicle (DMSO; control group) or
E217G (200 mM) for 20 min. To evaluate the role of MAPKs in
E217G-induced hepatocanalicular dysfunction, IRHCs were
preincubated with SB203580 (1 mM), a p38a/ß inhibitor,
PD980589 (5 mM), an inhibitor of the MAPKK upstream of
ERK1/2 (MEK1/2), or SP600125 (1 mM), a JNK1/2 inhibitor,
for 15 min., followed by addition of E217G for another 20-min
period. Co-inhibition of cPKC and PI3K was carried out by co-
administering their specific inhibitors Go¨6976 (1 mM) and WM
(100 nM), respectively.
Function and localization of Bsep and Mrp2 in IRHCs
Functional changes in Bsep and Mrp2 were evaluated by
assessing the canalicular vacuolar accumulation (cVA) of CGamF,
a fluorescent Bsep substrate [26,27], or glutathione methylfluor-
escein (GS-MF), a fluorescent Mrp2 substrate derived from
CMFDA; this latter compound diffuses passively, and is intracel-
lularly metabolized by esterases and glutathione S-transferases to
render GS-MF [28].
For transport studies, cells were washed twice with L-15 and
exposed to 0.3 mM CGamF [26] or 2.5 mM CMFDA [29] for
15 min; after that, images were captured using a digital camera
(Q-color5; Olympus America, Center Valley, PA) under a
fluorescence microscopy (Zeiss Axiovert 25). cVA was assessed
by determining the proportion of IRHCs (.200 per preparation)
accumulating in their canalicular vacuoles the fluorescent com-
pounds, as described [29]. Intracellular localization of Bsep and
Mrp2 was evaluated by confocal laser microscopy (Zeiss Pascal
LSM 5, Carl Zeiss, Walldorf, Germany). For this purpose, cells
were fixed with 4% paraformaldehyde in phosphate-buffered
saline, and immunostained with a rabbit anti-rat Bsep (1:100, 2 h;
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Kamiya Biomedical Co., Seattle, WA, USA), or with a mouse anti-
human MRP2 (1:100, 2 h; [M2III-6], Alexis Biochemicals, San
Diego, CA, USA), followed by incubation with a Cy2-conjugated
donkey anti-rabbit IgG or a Cy2-conjugated donkey anti-mouse
IgG (1:200, 40 min; Jackson ImmunoResearch Laboratory, West
Grove, PA). Densitometric analysis of confocal microscopy images
was performed along a line perpendicular to the canalicular
vacuole with ImageJ 1.34 m, as described [8]. The canalicular
space on Bsep/Mrp2-labeled IRHCs was identified by superpos-
ing each fluorescent image with its respective differential interface
contrast (DIC) image [5].
Colocalization of Mrp2/Bsep with Rab11a in IRHCs
Colocalization studies of Mrp2 and Bsep with Rab11a were
performed as previously described [30]. Transporters were stained
using the primary and secondary antibodies described above, and
Rab11a was detected by using two different specific antibodies: a
mouse monoclonal to Rab11a antibody (1:100, 2 h; Abcam,
Cambridge, MA) for colabeling with Bsep and a rabbit polyclonal
to Rab11a antibody (1:100, 2 h; Invitrogen) for colabeling with
Mrp2, followed by incubation with a Cy3-conjugated donkey anti-
mouse IgG and a Cy3-conjugated goat anti-rabbit IgG (1:200 1 h;
Jackson ImmunoResearch Laboratory, West Grove, PA), respec-
tively. To delimit the canalicular vacuoles, F-actin was stained by
adding Alexa Fluor 635 phalloidin (1:80, 1 h; Invitrogen, Carlsbad
CA) together with the secondary antibodies for Mrp2, Bsep and
Rab11a.
Western blot analysis of MAPK phosphorylation
Activation of p38, ERK1/2, and JNK1/2 was assessed by
evaluating by Western blotting the phosphorylation status of these
MAPKs in lysates of primary-cultured rat hepatocytes. Briefly,
isolated rat hepatocytes were obtained by collagenase perfusion, as
described [31], and cultured in 3-cm Petri dishes at a density of
26106 cells/mL. After 5 h of culture, cells were exposed to E217G
(200 mM) for 10–60 min, washed with cold phosphate-buffered
saline, and finally resuspended in cell lysis buffer and a protease
inhibitor cocktail. Aliquots containing an equivalent total protein
content, as determined by the Lowry procedure with BSA as the
standard [32], were subjected to sodium dodecyl sulfate/12%
polyacrylamide gel electrophoresis, electrotransferred to Immobi-
lon-P membranes and probed overnight with a rabbit anti-
phosphorylated p38 (1:300; D-8, Santa Cruz, CA, USA), a rabbit
anti-phosphorylated ERK1/2 (1:1000; Cell Signaling), and a
mouse anti-phosphorylated JNK1/2 (1:2000; Cell Signaling)
antibodies. Stripped membranes were reprobed with a rabbit
anti-ERK1/2 antibody (1:1000; Cell Signaling), a rabbit anti-
JNK1/2 antibody (1:1000; Cell Signaling) or a mouse anti-p38
(1:500; N-20, Santa Cruz Biotechnology). After using a donkey
anti-rabbit IgG secondary antibody or a goat anti-mouse IgG
(1:5000, 1 h; Thermo Fisher Scientific, Waltham, MA, USA), a
chemiluminescence reagent, and Hyperfilm ECL, phosphorylated
and total MAPKs bands were quantified by densitometry with
ImageJ 1.34 m.
Studies in IPRLs
Livers from bile duct-cannulated rats (Intramedic PE-10 tubing,
Clay Adams) were perfused in situ, as described elsewhere [8].
Transport activity of Mrp2 and Bsep in IPRL was evaluated by
measuring 2,4-dinitrophenyl-S-glutathione (DNP-SG) and tauro-
cholate excretion, respectively. For this purpose, sodium tauro-
cholate (2 mM) and CDNB (0.5 mM) were added to the perfusion
medium.
After a 20-min equilibration period, the p38 inhibitor
SB203580 (250 nM) or the ERK1/2 inhibitor PD98059 (5 mM)
or their solvent (DMSO; 370 mL/L) were added to the reservoir.
Fifteen min later, a 5-min basal bile sample was collected, followed
by administration of E217G (3 mmol/liver; single intraportal
injection, over a 1-min period), or its solvent in controls
[DMSO/10% BSA in saline (4:96)]. Bile was then collected at
5-min intervals for another 30-min period. Experiments were
considered valid only if the initial bile flow was greater than
30 mL/min/kg of body weight. Liver viability was evaluated by
monitoring lactate dehydrogenase release into the perfusate
outflow [33]; experiments exhibiting activities over 20 U/L were
discarded.
DNP-SG content in bile was measured by high-performance
liquid chromatography, as described [34]. Biliary bile salt
concentration was determined by a modification of the Talalay’s
method [35].
At the end of the perfusion period, a liver lobe was excised,
frozen in isopentane precooled in liquid nitrogen, and stored at
280uC for further immunofluorescence and confocal microscopy
analysis of Mrp2 and Bsep intracellular localization. F-actin
staining was carried out to demarcate the limits of the canaliculi, as
described [5,8]. Liver sections were fixed and stained as described
[6,7], followed by overnight incubation with the specific antibodies
against Bsep or Mrp2, and 1 h incubation with the appropriate
cyanine 2-conjugated secondary antibodies, and Alexa Fluor 568
phalloidin (1:100, 1 h) for F-actin. To ensure comparable staining
and image capture performance for the different groups belonging
to the same experimental protocol, liver slices were prepared on
the same day, mounted on the same glass slide, and subjected to
the staining procedure and confocal microscopy analysis simulta-
neously. Quantification of the degree of Bsep and Mrp2 endocytic
internalization was performed on confocal images using ImageJ
1.34 m (National Institutes of Health), as described [5].
Statistical Analysis
Results are expressed as mean 6 standard error of the mean
(SEM). Statistical analysis was performed with one-way analysis of
variance followed by the Newman-Keuls test. The variances of the
densitometric profiles of Bsep and Mrp2 localization were
compared with the Mann-Whitney U test. P values,0.05 were
considered to be statistically significant.
Figure 1. E217G activates the MAPK signalling pathway. (A) left panel: representative Western blottings of phospho (p)-p38, p-ERK1/2, p-
JNK1/2 and total forms of all these MAPK types were obtained from whole cellular lysates of primary-cultured rat hepatocytes incubated with E217G
(200 mM) for 10 to 60 min, or with E217G (200 mM) for 20 min in cells pretreated with the PI3K inhibitor wortmanin (WM, 100 nM) or with the cPKC
inhibitor Go¨6976 (Go¨, 1 mM) for 15 min. A (right panel), and B and C panels show phosphorylation status of all MAPK types evaluated (calculated as
the p-MAPK to total MAPK ratio for each experimental condition). An arbitrary value of 100 was assigned to the band of highest densitometric
intensity in every Western blot before the ratio was calculated. The results are shown as mean 6 SEM (n = 5). *P,0.05 vs. control (cells treated only
with DMSO), and #P,0.05 vs. E217G (20 min).
doi:10.1371/journal.pone.0049255.g001
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Results
E217G activates MAPKs
Western blots of phospho(p)-p38 (Fig. 1; A, right panel), p-
ERK1/2 (Fig. 1; B) and p-JNK1/2 (Fig. 1; C) showed that E217G
increased the amount of each p-MAPK in a time-dependent
manner, with increments becoming apparent as soon as 10 min
after E217G administration. Pretreatment with the cPKC inhibitor
Go¨6976 (1 mM) or the PI3K inhibitor WM (100 nM) selectively
prevented the increase in p-p38 and p-ERK1/2, respectively
Figure 2. Effect of the inhibition of p38, ERK1/2 and JNK1/2, or the coinhibition of cPKC-ERK1/2, PI3K-p38, or p38-ERK1/2, on
E217G-induced impairment of the canalicular accumulation of the Bsep and Mrp2 fluorescent substrates in IRHCs. IRHCs were
incubated with E217G (200 mM, 20 min) (or DMSO in controls), with or without pretreatment for 15 min with the JNK1/2 inhibitor SP600125 (1 mM),
the ERK1/2 inhibitor PD98059 (PD; 5 mM), and/or the p38 inhibitor SB203580 (SB; 1 mM), together or not with the cPKC inhibitor Go¨6976 (Go¨; 1 mM) or
PI3K inhibitor wortmanin (WM; 100 nM). Canalicular accumulation CGamF (Bsep substrate, panel A) and GS-MF (Mrp2 substrate, panel B) was
determined as the percentage of couplets displaying visible fluorescence in their canalicular vacuoles from a total of at least 200 couplets per
preparation. The results are expressed as percentages of the control group and are shown as mean6 SEM (n = 3–4). *P,0.05 vs. E217G, and
#P,0.05
vs. E217G-WM, E217G-Go¨, E217G-PD or E217G-SB.
doi:10.1371/journal.pone.0049255.g002
MAPKs in Estradiol 17b-D-Glucuronide Cholestasis
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e49255
(Fig. 1), indicating that activation of p38 depends upon cPKC
whereas activation p-ERK1/2 depends upon PI3K. Instead,
pretreatment with either WM or Go¨6976 prevented the increase
in JNK2 phosphorylation induced by E217G; although a clear
trend towards prevention of JNK1 phosphorylation was also
observed, this prevention only achieved statistical significance for
Go¨6976.
E217G-induced impairment of Bsep and Mrp2 transport
function and localization in IRHCs involves p38- and
ERK1/2-dependent, additive mechanisms
Functional studies in IRHCs revealed that both the p38
inhibitor SB203580 and the ERK1/2 inhibitor PD98059 signif-
icantly prevented E217G-induced impairment in cVA of both the
Bsep and the Mrp2 substrates (CGamF and GS-MF, respectively;
Fig. 2). Contrarily, the JNK1/2 inhibitor SP600125 was without
effect, suggesting that JNK1/2 activation does not play a causal
role in E217G-induced cholestasis.
The effect of E217G on Bsep and Mrp2 transport activity was
accompanied by changes in the localization status of these
transporters (Fig. 3, top panels). In control IRHCs, the carrier-
associated fluorescence was localized mainly in the canalicular
vacuoles, whereas in the E217G-treated group, there was extensive
relocalization of the fluorescence from the canalicular zone to the
cellular body, indicating endocytosis of the canalicular carriers.
This phenomenon was markedly prevented by either p38 or
ERK1/2 inhibition (Fig. 3, top panels). This was confirmed by
densitometric analysis, which showed a flatter Bsep and Mrp2
fluorescence profile in E217G-treated IRHC (Fig. 3, lower panels).
ERK1/2 or p38 inhibition prevented partial or totally this
relocalization, as densitometric curves were statistically different
from that of E217G alone (Fig. 3, lower panels).
The preventive effects of PD98059 and SB203580 on CGamF
and GS-MF secretory failures were additive in nature (Fig. 2),
suggesting that ERK1/2 and p38 act through different but
complementary mechanism. However, additivity of effects can
only be assumed when recorded at concentrations of the inhibitors
producing maximal effects individually. This was actually the case,
since the protective effects of each of them remained virtually the
same at concentrations 5-time higher than those used here in
additivity studies (data not shown).
cPKC-p38 and PI3K-ERK1/2signalling pathways are
involved in E217G-induced canalicular secretory failure in
an additive manner
We have previously demonstrated that the cholestatic effect of
E217G is partially prevented by the selective inhibition of cPKC
[8] and of PI3K [9], and that these kinases play a partial and
Figure 3. Effect of inhibition of p38 or ERK1/2, and coinhibition of cPKC-ERK1/2, PI3K-p38, or p38-ERK1/2 on E217G-induced
retrieval of Bsep and Mrp2 in IRHCs. The upper panels show representative confocal immunofluorescence images of the localization of Bsep and
Mrp2 in DMSO-treated (control) or E217G (200 mM)-treated IRHCs, with or without the p38 inhibitor SB203580 (SB; 1 mM) or the ERK1/2 inhibitor
PD98059 (PD; 5 mM), in combination or not with the cPKC inhibitor Go¨6976 (Go¨; 1 mM) or PI3K inhibitor wortmanin (WM; 100 nM). The lower panels
show the densitometric analysis of the fluorescence intensity along a line (8 mm) perpendicular to the center of the canalicular vacuole (from +4 to
24 mm). The statistical analysis of the profiles of fluorescence showed a significant change in the E217G-treated group (P,0.05; number of analyzed
canalicular vacuoles .10), but this reverted to normal in the E217G-SB, E217G-PD, E217G-PD-SB, E217G-Go¨-PD and E217G-WM-SB groups for Bsep and
Mrp2.
doi:10.1371/journal.pone.0049255.g003
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complementary role in E217G-induced cholestasis. Since we
demonstrated here that cPKC and PI3K are selectively involved
in p38 and ERK1/2 activation, respectively (Fig. 1), we tried to
reproduce these selective dependencies in the functional field
(Fig. 2). As expected, there was a lack of additivity in the protective
effects when Go¨6976 (cPKC inhibitor) and SB203580 (p38
inhibitor) were added together, and the same holds true when
WM (PI3K inhibitor) was added together with PD98059 (ERK1/2
inhibitor). On the other hand, adittivity was observed when cross-
combinations of these inhibitors were used (i.e., Go¨6976 plus
PD98059, or WM plus SB203580). Besides, the pretreatment of
IRHCs with these same combinations of inhibitors markedly
prevented the E217G-induced internalization of canalicular
carriers (Fig. 3, upper panels), resulting in control-like densito-
metric curves of Bsep/Mrp2 localization (Fig. 3, lower panels).
This supports the fact that cPKC-p38 and PI3K-ERK1/2
signalling pathways act in parallel and in a complementary
manner to account for E217G cholestatic effects.
p38-ERK1/2 co-inhibition prevents the colocalization of
Bsep/Mrp2 with the endosomal protein Rab11a induced
by E217G
In E217G cholestasis, canalicular carriers are rapidly endocy-
tosed from the canalicular membrane, and can return back to this
membrane, presumably from the apical recycling endosomes
(ARE) [1]. To visualize this phenomenon, and its prevention by
MAPK inhibitors, we evaluated in IRHCs the colocalization status
of canalicular carriers with the endosomal protein Rab11a, a
marker of ARE that has been shown to colocalize with apically
endocytosed proteins in hepatocytes [36]. Using this approach, no
colocalization was observed between Rab11a (red) and Bsep or
Mrp2 (green) in controls (Fig. 4). Contrarily, E217G induced
Figure 4. Effect of E217G on colocalization of Rab11a with Mrp2 or Bsep in IRHCs. Immunofluorescence confocal images showing staining
of Mrp2 or Bsep (green) and Rab11a (red) in IRHCs treated with DMSO (control), the ERK1/2 inhibitor PD98059 (PD; 5 mM), the p38 inhibitor SB203580
(SB; 1 mM), or both inhibitors together. Colocalization of Rab11a with Mrp2 or Bsep in the E217G-treated group is indicated by orange-yellow
fluorescence in merged images. Insets depict F-actin staining, which was used to demarcate the limits of the canalicular vacuoles.
doi:10.1371/journal.pone.0049255.g004
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colocalization of canalicular carriers with Rab11a (yellow/orange
merge). IRHCs pretreated with either SB203580 or PD98059
showed lack of colocalization, as in controls; this indicates that
either or both the carrier internalization towards ARE was
prevented or the carrier reinsertion from ARE has been
accelerated.
p38 is involved in the initial impairment of bile secretory
function induced by E217G, whereas ERK1/2 blocks its
recovery in the IPRL model
The IRHC model revealed the existence of two complementary
mechanisms accounting for E217G-induced cholestasis, which
differentially depends upon the cPKC/p38 and PI3K/ERK1/2
pathways (see above). The nature of these two cholestatic
mechanisms cannot however be ascertained by using this
approach. Using the IPRL model, which unlike IRHCs allow
for the dissection of mechanisms occurring separately in time, we
had shown a differential role for cPKC and PI3K in E217G-
induced cholestasis: whereas cPKC is involved in the initial
reduction in bile flow due to transporter endocytosis, PI3K (via
Akt) blocks the otherwise spontaneous reinsertion of the endocy-
tosed transporters [9]. We therefore used this model to assess
whether p38 and ERK1/2 reproduce the cholestatic mechanisms
induced by their respective upstream activators, cPKC and PI3K.
The bolus administration of E217G induced a 61% decrease in
bile flow within 10 min, which did not recover throughout the
perfusion period (Fig. 5, upper panel). This was accompanied by a
decrease in the biliary excretion of the Mrp2 and Bsep substrates
DNP-SG and taurocholate, respectively (Fig. 5, middle and lower
panels). Whereas the p38 inhibitor SB203580 (250 nM) prevented
this initial drop, the ERK1/2 inhibitor PD98059 (5 mM) had little,
if any, effect on this event. In contrast, PD98059 accelerated the
recovery of both bile flow and biliary excretion of Mrp2 and Bsep
substrates from 15 minutes of E217G administration onwards.
SB203580 and PD98059, when added alone, did not induce any
changes in these parameters (data not shown).
Prevention of the biliary secretory failure induced by E217G by
SB203580 and PD98059 was accompanied by the recovery of the
normal canalicular localization of Bsep and Mrp2 at the end of the
perfusion period (Fig. 6). In control livers, transporter-associated
fluorescence was confined to the canalicular space (from21 mm to
+1 mm). In E217G-treated livers, relocalization of intracellular
fluorescence associated with both carriers from the canalicular
space to the pericanalicular area was apparent, as indicated by the
decrease in the fluorescence intensity in the canalicular area
together with the increased fluorescence at a greater distance from
the canaliculus (P,0.001 vs. controls); this indicates endocytic
internalization of the carriers. Whereas SB203580 and PD98059
itself did not induce any changes in transporter localization (data
not shown), both inhibitors extensively prevented the internaliza-
tion of Bsep and Mrp2, as illustrated by a control-like pattern of
the Bsep and Mrp2 distribution profiles in livers pretreated with
the inhibitors, as compared with the E217G-treated group
(P,0.005 vs. E217G; n=20–50 canaliculi per experimental group,
from three independent experiments). This supports our conten-
tion that p38 contributes to E217G-induced cholestasis by
retrieving canalicular carriers from their membrane domain in a
cPKC-dependent manner. On the other hand, ERK1/2 would
hinder the spontaneous retargeting of the endocytosed transporters
by acting downstream PI3K.
Discussion
This study provides further insights into the intracellular
signalling pathways involved in E217G-induced cholestasis.
First, we demonstrated here for the first time that E217G
activates the main MAPK types, i.e., p38, ERK1/2 and JNK1/2
(see Fig. 1). Furthermore, the activation of p38 and ERK1/2
Figure 5. Effect of inhibition of p38 or ERK1/2 on E217G-
induced decrease of bile flow and biliary secretion of the Mrp2
and Bsep substrates DNP-SG and taurocholate, respectively, in
the perfused rat liver (IPRL) model. IPRLs were treated with a
portal bolus of E217G (2 mmol/liver), or with the E217G vehicle DMSO
(control), in the presence and absence of the ERK1/2 inhibitor PD98059
(PD; 5 mM) or the p38 inhibitor SB203580 (SB; 250 nM). The effect of the
treatments on (A) bile flow, (B) DNP-SG excretion, (C) and taurocholate
excretion are shown. Results are expressed as the mean 6 SEM (n = 4).
doi:10.1371/journal.pone.0049255.g005
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depended differentially on cPKC and PI3K, respectively. This
differential dependency is in line with evidence in the literature
showing a similar sequential activation, i.e. PI3K-ERK1/2
[12,37,38,39] and cPKC-p38 [40,41] in hepatocytes or HepG2
hepatoma cells.
The activation of these two signalling pathways by E217G
accounted for two independent and complementary cholestatic
mechanisms; whereas the cPKC-p38 signalling pathway was
essential for the acute cholestatic effect induced by E217G, a
phenomenon largely attributed to the endocytic internalization of
Mrp2/Bsep, PI3K-ERK1/2 promoted the intracellular retention
of these transporters during the cholestatic phenomenon (see
Fig. 7). A similar complementarity had been demonstrated by us
for their respective upstream activators, i.e. cPKC and PI3K/Akt
[9].
The mechanism by which p38 mediates endocytosis results
elusive because of our poor knowledge on the molecular
mechanisms that trigger this process, but several reports in other
cell models provide some hints. p38 accelerates clathrin-mediated
endocytosis of several ligand receptors, such as epidermal growth
factor receptor (EGFR) [42], the opioid receptors m and d [43],
and the glutamate receptor [44], and there are several similarities
between the internalization process of these receptors and that of
Bsep. Like them, Bsep is internalized in a clathrin-dependent
manner through a mechanism requiring the adaptor protein AP-2
[45], and AP-2 phosphorylation by p38 is essential for cargo
recruitment to clathrin-coated pits, as shown for EGFR endocy-
tosis [46]. Another putative p38 target is the Rab GDP
dissociation inhibitor Rab:GDI. This protein stimulates the
membranes/cytosol recycling of Rab5, a protein that coordinates
formation of clathrin-coated vesicles and their fusion with early
endosomes, thus increasing endocytic rate [47]. p38 increases
Rab:GDI activity by direct phosphorylation at serine-121 [48].
Whether similar regulations for the endocytic process apply to
Bsep, and whether Mrp2 shares with Bsep clathrin-mediated
endocytic mechanisms remains to be ascertained. The latter is
Figure 6. Effect of inhibition of p38 or ERK1/2 on E217G-induced retrieval of Bsep and Mrp2 in perfused rat livers at the end of the
perfusion period. The upper panels show representative confocal images showing co-staining of Mrp2 or Bsep (green) with F-actin (red; used to
visualize the bile canaliculus limits), illustrative of the endocytic internalization of Mrp2 and Bsep induced by E217G (2 mmol/liver), and its protection
by the ERK1/2 inhibitor PD98059 (PD; 5 mM) or the p38 inhibitor SB203580 (SB; 250 nM). The lower panels show a densitometric analysis of the
intensity of fluorescence associated with Bsep and Mrp2 along a 6 mm line perpendicular to the canaliculus (from 23 mm to +3 mm from the
canalicular center), corresponding to the confocal images in the upper panels.
doi:10.1371/journal.pone.0049255.g006
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however probable, since endocytosis of Mrp2 in E217G-induced
cholestasis is a microtubule-independent event [7], and the same
applies for clathrin-dependent endocytosis [49].
Our results also show that the PI3K/ERK1/2 pathway is
involved in the intracellular retention of the endocytosed
transporters, which otherwise would rapidly return to the
canalicular membrane in a microtubule-dependent manner [7].
The nature of this vesicular trafficking is speculative at this point,
but presumably involves the latest, microtubule-dependent
exocytic step of the transcytotic route, which occurs via apical
recycling endosomes (ARE). This is supported by the facts that: 1)
Bsep and Mrp2 colocalize with the ARE marker Rab11a (see
Fig. 4), 2) Mrp2 and Bsep colocalize on the same vesicles with both
the microtubule motor dynein and polymeric immunoglobulin
receptor (pIgR), a surface protein that is transcytosed via ARE
from the basolateral to the apical membrane [50], 3) insertion of
Bsep back to the canalicular membrane from ARE is a
microtubule-dependent process [51], and 4) ARE is interconnect-
ed in a microtubule-dependent manner with apical early
endosomes (AEE), the first station on the endocytic pathway
involved in apical endocytosis [49]. Due to the microtubule-
dependent nature of the exocytic process, microtubule-based
motor proteins are a likely target for ERK1/2 modulation of
canalicular transporter exocytosis. In line with this, ERK1/2
impairs binding activity of the microtubule motor kinesin-1 [52];
this protein is enriched in both AEE and ARE in liver (40% and
45% of total kinesin content, respectively) [53], and may therefore
play a key role in the trafficking of canalicular transporters from
AEE to ARE and in their exocytosis from ARE, which are both
microtubule-dependent events [49].
The dependency of E217G-induced cholestasis on both p38 and
ERK1/2 results somewhat paradoxical with respect to other
reports showing that both MAPK types are involved in choleretic
phenomena, such as those induced by the bile salt tauroursodeox-
ycholate (TUDC) [54,55,56] and cAMP [57]. For example,
TUDCA stimulates biliary excretion of the choleretic bile salt
taurocholate via an integrin-dependent dual signalling pathway
that involves both Ras/Raf/MEK/ERK1/2 and Src/p38 signal-
ling pathways [54,55,56,58]; of note, activation of ERK1/2 by
TUDC depends on PI3K [59] but not on PKC [55], in agreement
with our results (see Fig. 1). The p38-mediated stimulation of
taurocholate excretion by TUDCA was due to an enhanced Bsep
trafficking from the Golgi compartment to the canalicular
membrane [56], and the further insertion of Bsep into the apical
membrane [54], in a microtubule-dependent manner. The reason
for the paradoxical pro-cholestatic and pro-choleretic effects of
MAPKs is unclear at present, but several possibilities arise. MAPK
activation is a highly compartmentalized process, which requires
activation and localization in the organelle of scaffold proteins to
allow for the regional recruitment of MAPK cascade components
[60]. In quiescent hepatocytes, Raf-1 and MEK (MAPKK of
ERK) are restricted to early endocytic compartments [61].
Therefore, rapid effects on endosomal trafficking of a MAPK
modulating agent like E217G may be limited to this early
endosomal pathway, whereas the influence on Golgi/post-Golgi
pathway would require further localization of specific MAPK
Figure 7. Schematic representation of the signalling events involved in E217G-induced cholestasis by endocytic internalization and
further retention of canalicular transporters relevant to bile formation (Bsep, Mrp2). p38, acting downstream of cPKC, triggers endocytic
internalization of the apical carriers presumably towards apical early endosomes (AEE), the first intracellular endosomal compartment receiving
internalized proteins from the apical membrane, in a microtubule-independent manner (solid arrow). These transporters traffic to, and accumulate
into, apical recycling endosomes (ARE), from where they can be retargeted to the apical membrane during the recovery of the cholestatic process, in
a microtubule-dependent manner (dashed arrows). Activation of the PI3K/Akt/ERK1/2 signalling pathway halts this latter process, thus explaining the
increased colocalization of Bsep/Mrp2 with Rab11a, an ARE marker. This prolongs the cholestatic effect of E217G by impeding the fast, spontaneous
retargeting of intracellular transporters that would lead to a rapid recovery from the cholestatic injury.
doi:10.1371/journal.pone.0049255.g007
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scaffold proteins at this site [62]. In addition, E217G and TUDC
may activate different signalling pathways apart from MAPKs
that, by operating in concert with MAPKs, result in opposite final
effects. For example, TUDC-induced acceleration of the Golgi/
post-Golgi exocytic pathway depends upon dual activation of p38
and novel PKC isoforms [56], and we have shown that E217G
does not activate the novel PKC isoform e [8]. Alternatively, in a
cholestatic context, TUDC-induced MAPK-dependent choleretic
mechanisms may not be operative. Actually, MAPKs do not
mediate TUDCA anticholestatic effects in TLC-induced cholesta-
sis [23]. Finally, mediation of choleretic and cholestatic effects by
p38 may reflect a differential capability of cholestatic and
choleretic compounds to evocate p38 isoforms with opposite
effects. Only a and ß p38 isoforms are present in liver, and they
have been shown to exert opposite effects in other cell types [63].
Importantly, stimulation of Mrp2 apical translocation by cAMP,
which prevents E217G-induced internalization of canalicular
carriers [6], involves exclusively p38a [57]. It would be of interest
to find out whether p38a activity is decreased by E217G, and
whether cAMP reverses this decrease as part of its anticholestatic
action.
While further studies will be required to assess the specific
molecular mechanisms mediated by ERK1/2 and p38 to impair
the localization status of canalicular transporters in estrogen-
induced cholestasis, our results strengthen the idea that there is a
clear interplay between signalling cascades and intracellular
trafficking in this cholestasis, and that both MAPKs are key
players in its ethiology. Drugs that inhibit selectively MAPKs have
been used in preclinical and clinical studies with reasonable
success [64]. As far as our results correlate with clinical cholestatic
situations in humans, they should help to envisage new, feasible
therapeutic strategies to treat them.
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